Casey A. Maguire, Ph.D.

Assistant Professor of Neurology
Harvard Medical School

Casey A. Maguire obtained his B.S. from the University of Maine in 2000, and his Ph.D. from the Department of Microbiology and Immunology at the University of Rochester School of Medicine and Dentistry in 2006. He was a postdoctoral fellow at Massachusetts General Hospital from 2006-2010. He was next an Instructor from 2010-2013. Currently, he is an Assistant Professor of Neurology at Harvard Medical School with laboratory space at the MGH. His labatory is focused on the development of effective gene delivery vehicles for in vivo gene therapy of various genetic diseases including Alzheimer’s disease. The current focus of the Maguire lab is the development of a unique hybrid gene delivery system called vexosomes. Vexosomes are endogenously enveloped adeno-associated virus (AAV) vectors. The envelope is derived from extracellular vesicles (EVs) which are natural lipid based nanoparticles released by cells. We have showns that EVs have several properties which enhance AAV-mediated gene delivery.

Funded Research

Project Description Researchers Funding
Extracellular Vesicle-Based Targeting of CD33-Mediated Pathology for Alzheimer’s Disease Therapy

Alzheimer’s disease (AD) is a devastating disease for patient and family alike. Unfortunately, there is no effective treatment and conventional, drug based therapies have failed. Our lab has developed a therapeutic virus vector that the body’s immune defenses will tolerate and that efficiently delivers nucleic acid-based material into cells. In this case, the material is a gene therapy specifically tailored to manipulate the expression of CD33, a gene seen in mouse models to slow beta amyloid clearance and thus contribute to Alzheimer’s disease pathology.

2015 to 2016